Developing a new treatment for idiopathic pulmonary fibrosis
Official title: Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
Funded at Fibrobiologics, LLC · NIH-10696538 · Data updated 2026-11-12
This study is looking at a new treatment called M10 that might help people with idiopathic pulmonary fibrosis (IPF) by reducing the harmful changes in their lung cells, with the hope of being more effective and having fewer side effects than current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fibrobiologics, LLC NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $299,295 |
| NIH project number | 1R41HL167504-01A1 |
| Project ID | NIH-10696538 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
✕Less likely to help
Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on creating a novel peptide therapeutic agent aimed at treating idiopathic pulmonary fibrosis (IPF), a serious lung disease. The approach involves testing the effectiveness of a peptide called M10 in inhibiting the fibrotic processes in lung cells taken from IPF patients. By leveraging advancements in peptide formulation, the study aims to develop a treatment that is both effective and has fewer side effects compared to existing medications. The research will assess how well M10 can reduce the harmful characteristics of lung fibroblasts associated with IPF.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and less toxic treatment option for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have gone: While there have been advancements in peptide therapies, this specific approach targeting idiopathic pulmonary fibrosis is relatively novel and has not been extensively tested.
Where this research is happening
-
Fibrobiologics, LLC
Charleston, United States Active
Researchers
- Principal investigator: Bogatkevich, Galina S — Fibrobiologics, LLC
- Study coordinator: Bogatkevich, Galina S
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.